All comparisons

Educational Wellness Information Only

This platform provides peer-reviewed research summaries and educational content about peptides for wellness and optimization purposes. Nothing on this site is intended as medical advice, diagnosis, or treatment. We do not claim any peptide can diagnose, treat, cure, or prevent any disease. Always consult a licensed healthcare provider before beginning any wellness protocol.

Statements on this site have not been evaluated by the FDA. Compounded preparations are subject to applicable state and federal regulations. Availability and eligibility vary.

Immune comparison

ARA-290 vs LL-37

An educational, source-based comparison of ARA-290 and LL-37 — how each peptide works, what it's researched for, and what to know before going deeper.

Neuropathic · Immune Modulation
ARA-290

Erythropoietin-derived peptide researched for neuropathy and tissue repair.

Mechanism

A synthetic 11-amino-acid peptide derived from the erythropoietin molecule. Research indicates it retains the tissue-protective (non-erythropoietic) effects of EPO via the β-common receptor, without stimulating red blood cell production.

Research areas
  • Small-fiber neuropathy and sarcoidosis
  • Diabetic neuropathy
  • Ischemia-reperfusion injury
  • Autoimmune modulation
Considerations
  • Investigational; not FDA-approved.
  • Does not raise hematocrit like full EPO molecule.
Full ARA-290 profile →
Immune · Antimicrobial
LL-37

Human cathelicidin peptide with antimicrobial and immune-modulating activity.

Mechanism

The only human cathelicidin antimicrobial peptide. Research demonstrates broad antimicrobial activity against bacteria, viruses, and fungi, plus immunomodulatory effects on neutrophils, macrophages, and wound healing.

Research areas
  • Chronic biofilm infections
  • Wound healing and dermatology
  • Innate immune modulation
Considerations
  • Not FDA-approved.
  • Pro-inflammatory effects possible at higher doses.
Full LL-37 profile →

ARA-290 vs LL-37 — Key differences

  • Class: ARA-290 is classified as Neuropathic · Immune Modulation, while LL-37 is Immune · Antimicrobial.
  • Primary research focus: ARA-290small-fiber neuropathy and sarcoidosis; LL-37chronic biofilm infections.
  • Tag: Neuropathic pain · Immune vs Immune · Antimicrobial.

Related comparisons